Liu Qinghua, chief technology officer at the Chinese company Lonvi Biosciences in Shenzhen, said that thanks to the latest research results, in the coming years no one will suffer from cancer, while living up to 150 years will become a reality.
"Living to 150 years is an absolutely achievable goal. In a few years, this will be a reality. In five to ten years, no one will get cancer," Qinghua said, reports The New York Times.
Their optimism is based on the development of a new drug, which has shown impressive results in laboratory studies. The company that runs Qinghua claims to have isolated molecules “capable of killing zombie cells”, old and senescent cells, which do not die and damage surrounding cells. Eliminating these cells is one of the most promising approaches in the field of senolysis, a technology widely studied by institutes such as Mayo Clinic, Scripps Research Institute, and Buck Institute for Research on Aging.
These cells are linked to accelerated aging, chronic inflammation, type 2 diabetes, cardiovascular disease, and some forms of cancer. Studies published in peer-reviewed journals Nature, Cell and Science show that clearing senescent cells in animal models increases lifespan and improves physical and metabolic functions.
The company claims to have found a way to produce capsules with high concentrations of these molecules, giving the drug the potential to function as a oral senolytic, a class of drugs that is currently in early clinical trials around the world.
"This is not just another pill. This is the Holy Grail," said Lonvi Biosciences CEO Ip Zuo, known by the nickname Ziko, the Telegraph reports.
According to the company, combining these pills with a healthy lifestyle and regular medical care could help people live to 100 to 120 years, or even longer. It's worth noting that studies on longevity in humans are complicated and require long-term trials.
David Furman, an associate professor at the Buck Institute for Research on Aging, one of the world's leading gerontology centers, said the Chinese pills "look promising," but stressed that they need to be tested in large, controlled clinical trials that are immune to methodological errors. Currently, some senolytics (such as the combination dasatinib + quercetin) are being tested in humans, but results are still limited.
China remains one of the leading countries investing aggressively in anti-aging research. In addition to grape seed extract, Chinese companies are exploring substances such as goji berries, as well as supporting technologies such as cryogenic chambers, hyperbaric therapy, mitochondrial stimulation and stem cell bioengineering.
Shenzhen-based company Lonvi Biosciences has developed anti-aging pills based on the compound procyanidin C1 (PCC1), found in grape seed extract. PCC1 belongs to the polyphenol family and has been studied for its antioxidant and anti-inflammatory effects.
Studies conducted in Shanghai University and published in Nature Metabolism showed that PCC1 increased the lifespan of mice by about 10%, selectively destroying senescent cells and protecting healthy cells. In aged mice, improvements in muscle strength, physical activity, bone density, and metabolism were observed.
However, researchers emphasize that moving from results in animal models to successful clinical trials in humans requires years and rigorous verification. /Telegraph/
